amide/hemorrhage

BACKGROUND OF THE INVENTION Trauma to the brain or spinal cord caused by physical forces acting on the skull or spinal column, by ischemic stroke, arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, cerebral hemorrhage, encephalomyelitis, hydrocephalus,

BACKGROUND OF THE INVENTION Trauma to the brain or spinal cord caused by physical forces acting on the skull or spinal column, by ischemic stroke, arrested breathing, cardiac arrest, Reye's syndrome, cerebral thrombosis, cerebral embolism, the neurological problems caused by AIDS, cerebral

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention generally relates to blends of poly(ester amide) (PEA) polymers or copolymers with a low glass transition temperature (T.sub.g) and PEA polymers or copolymers with a high T.sub.g, which are useful for coating an implantable device

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention generally relates to blends of poly(ester amide) (PEA) polymers or copolymers with a low glass transition temperature (T.sub.g) and PEA polymers or copolymers with a high T.sub.g, which are useful for coating an implantable device

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention generally relates to poly(ester amide) block copolymers useful for forming a bioabsorbable device such as a stent or for coating an implantable device such as a drug-delivery stent. 2. Description of the Background Percutaneous

BACKGROUND OF THE INVENTION The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active

BACKGROUND OF THE INVENTION The present invention concerns novel amide derivatives of substituted quinoxaline 2,3-diones having utility as glutamate receptor antagonists. The fused ring quinoxaline 2,3-dione system is substituted at the a- or b-position by amide derivatives. The compounds are active

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention generally relates to poly(ester amide) block copolymers useful for forming a bioabsorbable device such as a stent or for coating an implantable device such as a drug-delivery stent. 2. Description of the Background Percutaneous

TECHNICAL FIELD The present invention relates to a method for producing an isoquinoline derivative or a salt thereof which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly as a

This application is a National Stage of PCT/JP11/069,187 filed Aug. 25, 2011 and claims the benefit of JP 2010-189392 filed Aug. 26, 2010. TECHNICAL FIELD The present invention relates to a method for producing an isoquinoline derivative or a salt thereof which is useful for preventing and treating

FIELD Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by

FIELD Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by

FIELD Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by

This invention relates to uses of compounds. In particular, it relates to the use of compounds in the treatment or prevention of diseases and biomedical conditions such as, seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent

BACKGROUND OF THE INVENTION Release of such cytokines as tumor necrosis factor .alpha.(TNF-.alpha.) and transforming growth factor .alpha.(TGF-.alpha.) can cause adverse reactions ranging from fever to sepsis. Many of these reactions are related to inflammation or autoinmuune conditions, such as